Deutsche Bank analyst Robyn Karnauskas came out with a few insights on Gilead Sciences, Inc. (NASDAQ:GILD), after conducting a survey and reviewing the latest IMS prescription data, which lead …
Deutsche Bank analyst Robyn Karnauskas came out today with an update on Gilead Sciences (NASDAQ:GILD), following the news that Anthem Inc. (NYSE:ANTM) chose GILD’s hepatitis C drug …
In a research report published today, Deutsche Bank analyst Robyn Karnauskas maintained a Buy rating on Gilead Sciences (NASDAQ:GILD), but reduced her price …
In a research report published Tuesday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on AbbVie (NYSE:ABBV) with an $80 price target, …
In a research report sent to investors today, Deutsche Bank analyst Robyn Karnauskas maintained a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) with a …
In a research report sent to investors today, Deutsche Bank analyst Robyn Karnauskas maintained a Hold rating on Sarepta Therapeutics (NASDAQ:SRPT) with a …
In a research report issued today, Deutsche Bank analyst Robyn Karnauskas downgraded shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) to Hold from Buy and reduced her …
In a research report released today, Deutsche Bank analyst Robyn Karnauskas assigned a Buy rating on Celgene Corporation (NASDAQ:CELG) and raised her share price target …
Gilead Sciences (NASDAQ: GILD) is a Foster City, California based bio-pharmaceutical company that discovers, develops and commercializes therapeutics for unmet medical areas in need. …
In a research note published today, Deutsche Bank analyst Robyn Karnauskas reaffirmed a Buy rating on Gilead Sciences (NASDAQ:GILD) with a $142 price target, …
